retatrutide trials weight loss New Phase 3 data just dropped 👀 Eli Lilly's trial reported average approaching 30%, with some patients achieving results historically associated with bariatric surgery. A few important caveats Experimental drug Retatrutide shows promising

A 2024 observational study raised questions about whether GLP-1 receptor agonists as a class may be associated with an increased risk of GORD-related conditions

Some online sellers use terms like research use only to avoid direct medical claims while still marketing products to consumers

[6] Eli Lilly and Company, 'Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial', Investor press release, Dec

doi: 10.1155/2020/8609213

A randomised controlled trial of exenatide once-weekly in alcohol use disorder showed mixed results overall, with possible effects in certain subgroups

Label every vial with the reconstitution date